ReviewFrontiers in endocrinology2026
Homocysteine combined with multi-index screening for pregnancy complications: a narrative review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Employing a narrative review approach, this article examines the value of combining homocysteine (Hcy) with multiple indicators for screening pregnancy complications. Hcy serves as a key biomarker in one-carbon metabolism and vascular endothelial function. Elevated Hcy levels are significantly correlated with adverse pregnancy outcomes, including preeclampsia (PE), fetal growth restriction (FGR), gestational diabetes mellitus (GDM), and intrahepatic cholestasis of pregnancy (ICP). Hcy levels are influenced by nutritional factors (folate, vitamin B12) and genetic factors (MTHFR polymorphisms). However, the predictive power of Hcy alone is limited due to variations in gestational age, ethnicity, nutritional status and genetic background. Recent studies have therefore explored combined screening strategies: Hcy together with platelet parameters helps differentiate the risk of ICP from that of GDM; adding uterine artery (UtA) Doppler ultrasonography improves the diagnostic sensitivity for detecting PE and FGR; integrating glycolipid metabolic markers (Glycosylated Serum Protein, Cystatin-C, apoB/apoA1) provides additional predictive value for adverse outcomes in GDM. Positioning Hcy as a functional endpoint of gene-nutrient interactions and combining it with nutritional and genetic assessments may facilitate early warning of pregnancy complications and enable individualized intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.